drugset / Trial / NCT00252863

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

NCT00252863

Phase 3 Completed 1600 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Symbicort dosed according to the Symbicort Maintenance and Reliever Therapy (SMART) concept is superior to standard asthma treatment according to the local German treatment guidelines.

Timeline

Start
2004-12
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 200 ug Inhaled
Subject Budesonide/Formoterol Unknown Inhaled
Subject Fluticasone Other / unclassified 250 ug Inhaled
Subject Fluticasone/Salmeterol Unknown Inhaled
Subject Formoterol Other / unclassified 4.5 ug Inhaled
Subject Montelukast Other / unclassified 10 mg
Subject Salbutamol Unknown 100 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled
Subject Terbutaline Small molecule 0.5 mg Inhaled
Subject Theophylline Small molecule 200 mg
Subject Theophylline Small molecule 300 mg

Indications